Eversept Partners LP Acquires New Holdings in Alto Neuroscience, Inc. $ANRO

Eversept Partners LP bought a new position in shares of Alto Neuroscience, Inc. (NYSE:ANRO) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 125,168 shares of the company’s stock, valued at approximately $2,814,000.

Other institutional investors have also made changes to their positions in the company. Quantinno Capital Management LP raised its stake in shares of Alto Neuroscience by 1.4% in the 1st quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after acquiring an additional 490 shares during the period. Torren Management LLC acquired a new position in shares of Alto Neuroscience in the 4th quarter worth approximately $62,000. XTX Topco Ltd boosted its position in shares of Alto Neuroscience by 32.2% during the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after purchasing an additional 5,078 shares during the period. Renaissance Technologies LLC boosted its position in shares of Alto Neuroscience by 6.3% during the 1st quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock worth $2,327,000 after purchasing an additional 6,100 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in Alto Neuroscience by 26.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock valued at $884,000 after purchasing an additional 8,148 shares during the last quarter.

Alto Neuroscience Stock Performance

NYSE:ANRO opened at $27.83 on Tuesday. Alto Neuroscience, Inc. has a 52 week low of $3.00 and a 52 week high of $28.85. The company has a fifty day simple moving average of $23.59 and a two-hundred day simple moving average of $21.62. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The company has a market cap of $976.48 million, a price-to-earnings ratio of -11.50 and a beta of 1.04.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, equities analysts anticipate that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on ANRO. Robert W. Baird cut their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Weiss Ratings upgraded Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Zacks Research downgraded Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Finally, JonesTrading cut their price objective on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.